{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002104","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.448378+00:00","generated_at":"2026-06-18T23:11:07.520575+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protalix BioTherapeutics enters $20M at-the-market equity offering with H.C. Wainwright","bullets":["ATM offering of up to $20M of common stock via H.C. Wainwright & Co. as sales agent.","Proceeds for general corporate purposes, including working capital and clinical trials.","Shares sold on NYSE American at prevailing market prices in 'at the market' transactions.","Agreement supplements existing July 2021 ATM facility (amended May 2022).","Offered under existing shelf registration statement (Form S-3, No. 333-264394)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002104","json":"https://secwatch.observer/filing/0001558370-23-002104.json","markdown":"https://secwatch.observer/filing/0001558370-23-002104.md","text":"https://secwatch.observer/filing/0001558370-23-002104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/0001558370-23-002104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/plx-20230227x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:11:07.520575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a4ebfbdf8282ffc8d70d175a88e3a91be8e5b0c9","claim":"Protalix BioTherapeutics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at shares of common stock with aggregate offering price of up to $20,000,000 (effective 2023-02-27).","evidence_excerpt":"On February 27, 2023, Protalix BioTherapeutics, Inc., a Delaware corporation (the \"Company\") entered into an At The Market Offering Agreement (the \"Sales Agreement\") with H.C. Wainwright & Co., LLC, as the Company’s sales agent (the \"Agent\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/0001558370-23-002104-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Value","value":"shares of common stock with aggregate offering price of up to $20,000,000"},{"label":"Effective","value":"2023-02-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}